Minimal Residual Disease Market, Share & Trends Analysis Report, By Product (Assay Kits & Reagents, Instruments), By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Flow Cytometry, Other Technologies), By Application (Hematological Malignancies, Lymphoma, Solid Tumors, Multiple Myeloma, Other Applications), By End User, By Region, and Segment Forecasts, 2025-2034

Global Minimal Residual Disease Market Size is valued at USD 1.4 Bn in 2024 and is predicted to reach USD 4.6 Bn by the year 2034 at a 12.8% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:

• Precision oncology, which tailors cancer treatment to the molecular characteristics of an individual's cancer, is a key driver of the MRD market.
• Increasing the sensitivity of MRD detection methods contributes to increasing the accuracy of treatment response assessment.
• North America dominated the market and accounted for a revenue share of global revenue in 2024.

The sophisticated nature of MRD detection methods, including next-generation sequencing (NGS), flow cytometry, and polymerase chain reaction (PCR), present challenges Minimal residual disease, also known as measurable residual disease or MRD, refers to the preclinical stages of diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM). After treatment, the cancer cells that remain in the body are referred to as a minimal residual disease. These cancer cells are undetected by imaging or physical exams, but sophisticated laboratory tests can discover them. The minimal residual disease is an essential indicator of disease progression and therapy response. The growing importance of the test is expected to drive growth in the worldwide minimum residual disease market in the coming years.

The global incidence of cancer has increased dramatically, which is projected to play a vital role in expanding the global minimal residual illness market. Patients are expected to see more precision in treatment using novel technology. These factors are likely to have an impact on growth. Furthermore, favorable government and private-sector initiatives for developing and adopting NGS technologies, technological advancements in cloud computing and data integration, and the availability of a technologically advanced healthcare research framework are all stimulating market growth. Additionally, the improved regulatory and reimbursement landscape for NGS-based diagnostic tests and increased genome mapping initiatives will fuel market expansion throughout the forecast period.

Market Segmentation:

The minimal residual disease market is segmented on the product, technology, application and end user. Based on product, the minimal residual disease market is divided into assay kits & reagents, instruments. Based on the technology, the minimal residual disease market is divided into polymerase chain reaction, next-generation sequencing, flow cytometry, and other technologies. Based on the Application, the minimal residual disease market is segmented into hematological malignancies, lymphoma, solid tumors, multiple myeloma, and other applications. Based on the end user, the minimal residual disease market is segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users.

The Assay Kits & Reagents segment is accounted as a major contributor to the minimal residual disease market.

Based on product, the minimal residual disease market is divided into assay kits & reagents, instruments. Among these, The Assay Kits & Reagents segment leads the MRD detection market due to its frequent and recurring use, as each test requires fresh reagents and assay kits. This segment benefits from the growing demand for repeat testing to monitor MRD levels during and after treatment, making it essential for effective disease management. Additionally, the expanding use of MRD detection in personalized medicine and clinical trials further fuels the demand for these consumables. In contrast, instruments such as flow cytometers and PCR machines represent a smaller yet stable market share, primarily driven by infrastructure investment rather than test volume.

The Polymerase Chain Reaction segment witnessed growth at a rapid rate.

Based on the technology, the minimal residual disease market is divided into polymerase chain reaction, next-generation sequencing, flow cytometry, and other technologies. Among these, the Polymerase Chain Reaction (PCR) segment has traditionally dominated the MRD detection market due to its widespread use, high specificity, and cost-effectiveness in routine clinical monitoring. However, Next-Generation Sequencing (NGS) is emerging as the fastest-growing segment, driven by its ultra-high sensitivity and ability to detect a broad spectrum of genetic alterations, making it increasingly favored in clinical trials and personalized treatment approaches. Flow cytometry also holds a significant share, especially in acute leukemias, offering rapid and relatively affordable results, though with lower sensitivity. 

The North American Minimal Residual Disease Market Holds A Significant Regional Revenue Share.

The North American minimal residual disease market is expected to register the highest market share in revenue shortly. The rising prevalence of blood malignancies and the increased investment in MRD research by government and private groups have grown healthcare affordability in the United States and the rise in knowledge and awareness among individuals in this region. In addition, Asia Pacific is projected to grow rapidly in the global minimal residual disease market due to government initiatives and large-scale genome sequencing studies funding to develop targeted treatments to contribute to market growth. Furthermore, the existence of key organizations and industries and the quick spread of paternity testing, genealogy, and personal health awareness drive market growth in this area over the forecast period.

Recent Developments:

• In Feb 2022, Personalis, Inc. and the Moores Cancer Center at the University of California San Diego Health partnered to offer clinical diagnostic testing for patients with advanced solid tumours and haematological malignancies. The Moores Cancer Center is recognized as a Comprehensive Cancer Center by the National Cancer Institute. The relationship facilitated the integration of Personalis' advanced and extensive genomic tumour profiling test into the healthcare services provided by UC San Diego. This enabled healthcare professionals and cancer patients to benefit from the test's ability to inform FDA-approved therapy decisions and provide access to potential treatment options in clinical trials.

Competitive Landscape

Some major key players in the Minimal Residual Disease Market:

• Adaptive Biotechnologies,
• ARUP Laboratories,
• Bio-Rad Laboratories Inc.,
• Cergentis B.V.,
• Hoffmann-La Roche Ltd.,
• ICON Plc,
• Invivoscribe Inc.,
• Laboratory Corporation of America Holdings,
• Mission Bio,
• Natera Inc.,
• NeoGenomics Laboratories,
• OPKO Health Inc.,
• Sysmex Corporation

Minimal Residual Disease Market Report Scope:

Segmentation Of Minimal Residual Disease Market

Minimal Residual Disease Market By Product

• Assay Kits & Reagents
• Instruments

Minimal Residual Disease Market By Technology

• Polymerase Chain Reaction
• Next-Generation Sequencing
• Flow Cytometry
• Other Technologies

Minimal Residual Disease Market By Application

• Hematological Malignancies
  • Leukemia
    • Myeloid Leukemia
    • Lymphocytic Leukemia
    • Other Leukemias
  • Lymphoma
    • Non-Hodgkin Lymphoma
    • Hodgkin Lymphoma
  • Solid Tumors
  • Multiple Myeloma
  • Other Applications

Minimal Residual Disease Market By End User

• Hospitals & Specialty Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Other End Users

By Region-

North America-

• The US
• Canada

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Mexico
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa